

Substitute for form 1449/PTO, based on PTO/SB/08A, 07/08/03 <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number <b>10/680,076</b>
		Filing Date <b>October 6, 2003</b>
		First Named Inventor <b>Bell et al.</b>
		Art Unit <b>1614 1624</b>
		Examiner Name <b>Not assigned COLEMAN</b>
		Attorney Docket Number <b>36-02</b>

*SEARCHED & INDEXED NOV 25 2003  
U.S. PATENT & TRADEMARK OFFICE*

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initial*	Cite No. <sup>1</sup>	Document Number (US-)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise) class subclass
BC		6,342,492	01/29/02	Bell	514 183
BC		6,335,339	01/01/02	Arenas et al.	514 245
BC		5,663,161	09/02/97	Bell	514 183
BC		5,565,562	10/15/96	Parker et al.	540 465
BC		2002/0019423	02/14/02	Bell	514 360

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No. <sup>1</sup>	Foreign Patent Document Number (include WIPO country code )	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)	T <sup>2</sup>
BC		WO96/025167	08/22/96			
BC		JP 08-27129	01/30/96			

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initial*	Cite No. <sup>1</sup>	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BC		Bell, T.W. et al. (March 2002), "Specific CD4 Down-modulating Compounds with Potent Anti-HIV and HHV-7 Activity," Abstract, 15 <sup>th</sup> Intl. Conference on Antiviral Research, Prague, Czech Republic, March 17-21, 2002	
BC		Chieco-Bianchi, L. et al. (1989), "CD4 modulation and inhibition of HIV-1 infectivity induced by monosialoganglioside GM1 in vitro," AIDS 3:501-507	
BC		Chowdhury, I.H. et al. (1990), "The Phorbol Ester TPA Strongly Inhibits HIV-1-induced Syncitia Formation but Enhances Virus Production: Possible Involvement of Protein Kinase C Pathway," Virology 176:126-132	
BC		Hoffman, T.L. et al. (1990), "Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein," Proc. Natl. Acad. Sci. USA 96:6359-6364	

Examiner Signature	Brenda Coleman	Date Considered	Sept. 29, 2006
--------------------	----------------	-----------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional).

<sup>2</sup>Applicant is to place a check mark here or "x" if English language Translation is attached.

\*\* Structures only

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B		Application Number	10/680,076
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	October 6, 2003
		First Named Inventor	Bell et al.
		Art Unit	1614 1624
		Examiner Name	Net-assigned COLEMAN
		Attorney Docket Number	36-02

Examiner Initial*	Cite No. <sup>1</sup>	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BC		Kabat, D. et al. (1994), "Differences in CD4 Dependence for Infectivity of Laboratory-Adapted and Primary Patient Isolates of Human Immunodeficiency Virus Type 1," J. Virol. 68:2570-2577	
BC		Kolchinski, P. et al. (March 2001), "Increased Neutralization Sensitivity of CD4-Independent Human Immunodeficiency Virus Variants," J. Virol. 75:2041-2050	
BC		Layne, S.P. et al. (1990), "HIV requires multiple gp120 molecules for CD4 mediated infection," Nature 346:277-279	
BC		Neudorf, S. et al. (1989), "Expression of the CD4 Molecule of Acute Nonlymphocytic Leukemia (ANLL) Cell Lines," J. Clin. Lab. Anal. 3:312-315	
BC		Platt, E.J. et al. (1997), "Infectious Properties of Human Immunodeficiency Virus Type 1 Mutants with Distinct Affinities for the CD4 Receptor," J. Virol. 61:883-890	
BC		Schols, D. et al. (1989), "Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor," Proc. Natl. Acad. Sci. USA 86:3322-3326	
BC		Vermeire, K. et al. (January 2003), "The Anti-HIV Potency of Cyclotriazadisulfonamide Analogs is Directly Correlated with Their Ability to Down-Modulate the CD4 Receptor," Mol. Pharmacol. 63:203-210	
BC		Vermeire, K. et al. (October 2002), "CADA Inhibits Human Immunodeficiency Virus and Human Herpesvirus 7 Replication by Down-modulation of the Cellular CD4 Receptor," Virology 302: 342-353	
BC		Zhang, Y. et al. (1999), "Selective activity of various antiviral compounds against HHV-7 infection," Antiviral Res. 43:23-35	

Examiner Signature	Brenda Coleman	Date Considered	Sept. 29, 2006
--------------------	----------------	-----------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional).

<sup>2</sup>Applicant is to place a check mark here or "x" if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>		Application Number		10680076	
		Filing Date		2003-10-06	
		First Named Inventor		Thomas Bell	
		Art Unit		1624	
		Examiner Name		COLEMAN, Brenda Libby	
		Attorney Docket Number		36-02	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1						

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Ts

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10680076
Filing Date	2003-10-06
First Named Inventor	Thomas Bell
Art Unit	1624
Examiner Name	COLEMAN, Brenda Libby
Attorney Docket Number	36-02

*BC* 1

BELL, T.W., et al., Synthesis and Structure - Activity Relationship Studies of CD4 Down-Modulating Cyclotriazadisulfonamide (DADA) Analogues, J. Med. Chem. 2006, 49, 1291-1312. Published on Web 02/02/2006.



If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	<i>Brenda Coleman</i>	Date Considered	<i>Sept. 29, 2006</i>
--------------------	-----------------------	-----------------	-----------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.